



an Open Access Journal by MDPI

Diagnostic and Therapeutic Approach to Pancreatic Cancer

Guest Editor:

Dr. Sanchita Rauth

University of Nebraska Medical Center, Omaha, NE, USA

Deadline for manuscript submissions: closed (30 June 2023)

Message from the Guest Editor

Recently, immunotherapies, such as checkpoint inhibitors (CTLA-4, PDL1) have been investigated (either alone or combined with chemotherapy) for the treatment of PC; however, most have proven to be less effective. Another emerging area for PC treatment includes the targeting of tumor microenvironment. Given that PC consists of dense and the PC microenvironment is highly stroma immunosuppressive, molecules or mechanisms that are involved with PC microenvironment are, thus, under active investigation. Beyond these, DNA damage repair proteins (PARP) inhibitors have also been examined for their potential to treat PC. Another obstacle in the field of PC is the lack of methods for early detection of pancreatic tumors. Recent studies have focused on identifying biomarkers; however, no biomarkers have yet entered clinical trials. The process of understanding the early detection and management of PC is dependent on knowledge of the basic tumor biology as well as determining the disease course (such as risk factors, treatment response, and disease progression) at a population level.









an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine* (*miscellaneous*))

Contact Us

Biomedicines Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/biomedicines biomedicines@mdpi.com X@Biomed_MDPI